A new study published in Nature has uncovered a novel mechanism by which aspirin inhibits cancer metastasis by strengthening the body’s immune response.
Researchers at the University of Cambridge and international collaborators have demonstrated that aspirin enhances T-cell immunity by counteracting platelet-derived thromboxane A2 (TXA2), suppressing the body’s natural defences against spreading cancer cells.
Metastasis, the primary cause of cancer-related deaths, occurs when cancer cells spread from the primary tumour to distant organs. The study reveals that TXA2 suppresses T-cell activation via the guanine exchange factor ARHGEF1, thereby reducing the immune system’s ability to attack metastatic cancer cells. By blocking TXA2 production through aspirin or other cyclooxygenase-1 (COX-1) inhibitors, T cells regain their ability to eliminate metastases in the lungs and liver.
Key Findings:
Aspirin’s Anti-Metastatic Role: Aspirin disrupts an immunosuppressive pathway in T cells, preventing cancer cells from evading the immune system.
TXA2 Suppression Mechanism: TXA2 impairs T-cell function through ARHGEF1-dependent pathways, reducing their ability to fight metastasis.
COX-1 as a Therapeutic Target: Inhibiting platelet COX-1 significantly reduces metastasis, highlighting its potential as a target for new anti-metastatic treatments.
Potential Clinical Implications: These findings could lead to more effective, low-cost and accessible therapies for preventing metastatic recurrence in cancer patients.
Lead researcher Dr Jie Yang from the University of Cambridge’s Department of Pathology stated, “Our findings offer a new perspective on how aspirin works against metastasis. This research explains aspirin’s long-observed benefits in cancer survival and suggests new avenues for targeted immunotherapies.”
Dr Jie Yang is a member of Professor Rahul Roychoudhuri research group.
The study reinforces previous epidemiological evidence linking aspirin use to reduced cancer mortality and underscores the importance of immune-based strategies in cancer treatment. Future research will focus on refining therapies that target the TXA2-ARHGEF1 pathway while minimizing potential side effects.